Monday, April 8, 2013

Is It Time to Write a Prescription for Coffee? Coffee and Liver Disease

Gastroenterology

Volume 144, Issue 4 , Pages 670-672, April 2013

Is It Time to Write a Prescription for Coffee? Coffee and Liver Disease

Dawn M. Torres Stephen A. Harrison Division of Gastroenterology, Department of Medicine, Walter Reed National Military Medical Center, Washington, DC Division of Gastroenterology, Department of Medicine, San Antonio Military Medical Center, Fort Sam Houston, Texas published online 22 February 2013.

Obesity, diabetes, the metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD) are on the rise in the United States, with upwards of 40% of the adult population currently meeting criteria for NAFLD. Approximately 10%–20% of patients with NAFLD meet criteria for nonalcoholic steatohepatitis, with a markedly increased risk of developing cirrhosis and/or hepatocellular carcinoma (HCC).1 Therapeutic interventions to mitigate disease on a population level have been limited and lifestyle modification, although effective, is difficult to sustain over time.

Coffee is ubiquitous in our society and has recently been shown to be inversely associated with total and cause-specific mortality.2 Specific to the study of liver disease, coffee has been demonstrated to have beneficial effects on weight gain, development of diabetes, the prevention of hepatic fibrosis in NAFLD, and other chronic liver diseases, including chronic hepatitis C, as well as reduction of HCC (Table 1). One large, retrospective survey of patients who participated in a NAFLD prevalence study found caffeinated coffee intake was associated with a significant reduction in fibrosis among biopsy-proven nonalcoholic steatohepatitis patients.3 Similarly, a meta-analysis with pooled data from 457,922 participants demonstrated an inverse association between coffee and risk of incident diabetes.4 Reduced hepatic fibrosis seems to be specific to caffeinated coffee and does not seem to be shared by other caffeinated beverages.5 There are approximately 1000 substances in coffee, including caffeine, diterphenoic alcohols, potassium, niacin, magnesium, and the anti-oxidants chlorogenic acid (CGA) and tocopherols.6 Diterphenoic alcohols, CGA, and caffeine are the most studied and are the focus of this discussion.

Table 1. Summary of the Major Human Studies Evaluating Coffee Intake and Chronic Liver Disease
First author and yearNo. of patientsDiagnosesFindings
Klatsky 199221128,934Californians undergoing physicalsCoffee drinking >4 cups per day had 1/5 the risk of alcoholic cirrhosis as non-coffee drinkers
Ruhl 2005225994NHANES III↑ALT declined with ↑ intake of coffee and caffeine; >2 cups per day vs no coffee; OR 0.56 for ↑ALT
Ruhl 2005239849NHANES I: Epidemiologic Follow-up Study>2 cups coffee daily vs <1 cup/d had <½ risk (OR, 0.43) of chronic liver disease
Bravi 200781551Meta-analysis of case-controlled studies of HCC in Europe/Japan41% ↓ risk of HCC among coffee vs never coffee drinkers
Larsson 2007242260 cases 239,146 non-casesMeta-analysis of 9 studies of HCC2 cups/d associated with 43% ↓ risk of liver cancer
Freedman 200925766HCV patients in the HALT-C trialRR for disease progression was 1.1 for <1 cup/d; 0.73 for 1–3 cups/d; and 0.47 for >3 cups/d vs no coffee
Modi 20104177121 HCV patients2.25 cups/d associated with ↓ liver fibrosis (OR, 0.33)
Leung WW 201126234HBV chronic carriersModerate coffee associated with ↓ HCC (OR, 0.54)
Johnson 20112763,257Adult, otherwise healthy Chinese≥3 cups/d associated with ↓ HCC (OR, 0.56)
Costentin 201128238HCV treatment-naïve patientsCaffeine >408 mg/d inversely associated with histologic activity (OR, 0.32)
Yamashita 201282554 males, 763 femalesHealthy Japanese workersCoffee consumption associated with ↑ adiponectin and ↓ leptin
Matsuura 2012293284Healthy Japanese civil servants≥4 cups/d associated with ↓ metabolic syndrome (OR, 0.79 vs 0.61)
Gutierrez-Grobe 20123073 subjects + 57 controlsNAFLD and controlsDose-dependent reduction in consumption of caffeine with increasing severity of steatosis
Freedman 20122229,119 males; 173,141 femalesNIH AARP Diet and Health StudyCoffee consumption inversely associated with total and cause-specific mortality
Molloy 20123306NAFLD patientsCaffeinated coffee associated with ↓ hepatic fibrosis in nonalcoholic steatohepatitis patients
Anty 201212195Severely obese patientsRegular coffee but not espresso associated with ↓ hepatic fibrosis in severely obese patients

AARP, American Association of Retired Persons; ALT, alanine aminotransferase; HALT, Hepatitis C Antiviral Long-term Treatment against Cirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; NHANES, National Health and Nutrition Examination Survey; OR, odds ratio; RR, relative risk.

The exact mechanisms by which coffee exerts its beneficial effects on the liver are still under investigation. The antifibrotic properties of coffee have been demonstrated in Wistar rats, where coffee was shown to protect against liver injury induced by thioacetamide, leading to reduced hepatic necroinflammation and fibrosis.7 Further study has suggested this is mediated by decreased expression of transforming growth factor-β and connective tissue growth factor.8 Another potential mechanism by which coffee exerts hepatoprotective effects was suggested by a Japanese study where coffee consumption was positively associated with adiponectin levels and inversely associated with leptin, high-sensitivity C-reactive protein, and liver enzymes.9

Coffee has also been shown to activate a family of enzymes involved in the hepatic detoxification process including uridine 5'-diphospho-glucuronosyltransferases (UGT), with initial studies demonstrating that the diterpines were responsible for the activation of UGT.10 Kalthoff et al11 further showed UGT activation by coffee to be independent of caffeine content as well as the major diterpines found in coffee, cafestol, and kahweol. In the accompanying editorial to this study, Gressner proposes both coffee and caffeine activate multiple hepatoprotective molecular signaling mechanisms and that a full understanding of the beneficial “blend” of coffee remains to be determined.12

The exact ingredients in coffee responsible for its beneficial effects on the liver are uncertain, although several substances as well as the method of preparation are thought to be of importance. Filtered coffee may provide the most benefit because it is thought to reduce cafestol and kahweol, which can raise serum cholesterol while maintaining CGA and caffeine content. Nonfiltered, boiled coffee includes Turkish coffee and coffee brewed in a French press and has been associated with an increase in low-density lipoprotein cholesterol as well as cardiovascular disease.13 Alternatively, these oily diterpenes may have anticarcinogenic properties as shown in cell culture study,14 possibly via anti-angiogenic processes,15 which may explain the reduced rates of HCC seen in a recent meta-analysis of 6 case-controlled studies.16

The polyphenols are another component of coffee that may explain some of coffee's metabolic benefits. The major polyphenol in coffee is CGA, which has shown potent anti-oxidant activity in vitro and cell culture as well as animal models and human epidemiologic studies.5 A recent study in obese rats fed a high-carbohydrate, high-fat diet demonstrated that filtered Columbian coffee extract with a high concentration of CGA can attenuate the development of glucose intolerance and NAFLD as well as hypertension and cardiovascular remodeling.17 These are compelling data, although they do not confirm that CGAs are the specific beneficial agent and validation in prospective, clinical trials is required.

Caffeine is another potential candidate that may be responsible for the beneficial effects of coffee on hepatic fibrosis. A large survey study with patients from the National Health and Nutrition Examination Surveys (2001–2008) demonstrated that caffeine intake specifically was associated with a lower risk of NAFLD in multivariate analysis (P < .001), although this observational study is limited because coffee intake and caffeine are so highly correlated in most individuals.18 The mechanism of action by which caffeine may have metabolic or hepatic benefits remains an area of investigation: Early data that showed anti-oxidant effects in vitro with high doses of caffeine19 have not been replicated in animal or human models and caffeine does not affect lipid or other metabolic panels. One study of 195 severely obese patients undergoing bariatric surgery evaluation even suggested that caffeine may not provide benefit; patients who consumed regular coffee had lower rates of hepatic fibrosis compared with those who consumed espresso beverages.20 A notable limitation of this study was that extra fructose consumption among those who drink espresso beverages could negate any potential benefit of the caffeine. In addition, espresso is made using high-pressure, boiling water through a column, is not filtered, and has a highly variable concentration of both caffeine and CGA, although generally with more caffeine than regular filtered coffee.

Based on the available data from predominantly observational trials, there seems to be a clinical benefit of coffee consumption for those patients at risk of developing hepatic fibrosis either from NAFLD or viral hepatitis. Rates of liver cancer and the development of metabolic syndrome may also be improved with daily moderate filtered coffee intake. CGA and caffeine are the best candidates for beneficial effects on hepatic fibrosis, and cafestol and kahweol may reduce rates of HCC. It is unclear whether any of these benefits are significant enough to “treat” patients with chronic liver disease and further study is required with standard doses of each of these purported therapies in appropriately powered, multicenter, randomized, controlled trials with both biochemical and hepatic histology as endpoints. In the interim, moderate daily unsweetened coffee ingestion is a reasonable adjunct to therapy for NAFLD patients that often includes lifestyle modification with diet and exercise.

Article Outline

References

Torres DM , Williams CD , Harrison SA . Features, diagnosis, and treatment of nonalcoholic fatty liver disease . Clin Gastroenterol Hepatol . 2012;10:837–858
View In Article
Abstract
Full Text
Full-Text PDF (3176 KB)
CrossRef
Freedman ND , Park Y , Abnet CC , et al. Association of coffee drinking with total and cause-specific mortality . N Engl J Med . 2012;366:1891–1904
View In Article
CrossRef
Molloy JW , Calcagno CJ , Williams CD , et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis . Hepatology . 2012;55:429–436
View In Article
CrossRef
Huxley R , Ying Lee CM , Barzi F , et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus . Arch Intern Med . 2009;169:2053–2063
View In Article
CrossRef
Modi AA , Feld JJ , Park Y , et al. Increased caffeine consumption is associated with reduced hepatic fibrosis . Hepatology . 2010;51:201–209
View In Article
CrossRef
Bonita JS , Mandarano M , Shuta D , et al. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies . Pharmacol Res . 2007;55:187–198
View In Article
MEDLINE
CrossRef
Furtado KS , Prado MG , Aguiar E , et al. Coffee and caffeine protect against liver injury induced by thioacetamide in male Wistar rats . Basic Clin Pharmacol Toxicol . 2012;111:339–347
View In Article
Arauz J , Moreno MG , Cortes-Reynosa P , et al. Coffee attenuates fibrosis by decreasing the expression of TGF-β and CTGF in a murine model of liver damage . J Appl Toxicol . 2012 Aug 17; [Epub ahead of print]
View In Article
Yamashita K , Yatsuya H , Toyoshima H , et al. Association of coffee consumption with serum adiponectin, lepin, inflammation, and metabolic markers in Japanese workers: a cross-sectional study . Nutrition and Diabetes . 2012;2:e33
View In Article
Huber WW , Prustomersky S , Delbanco E , et al. Enhancement of the chemoprotective enzymes glucuronyosyl transferase and glutathione transferase in specific organs of the rat by coffee components kahweol and cafestol . Arch Toxicol . 2002;76:209–217
View In Article
MEDLINE
CrossRef
Kalthoff S , Ehmer U , Freiberg N , et al. Coffee induces expression of glucoronosyltransferase by the aryl hydrocarbon receptor and Nrf2 in liver and stomach . Gastroenterology . 2010;139:1699–1710
View In Article
Abstract
Full Text
Full-Text PDF (2592 KB)
CrossRef
Gressner OA . In the search of the magic bullet . Gastroenterology . 2010;139:1453–1457
View In Article
Full Text
Full-Text PDF (512 KB)
CrossRef
Ranheim T , Halvorsen B . Coffee consumption and human health: beneficial or detrimental? (Mechanisms for effects of coffee consumption on different risk factors for cardiovascular disease and type 2 diabetes mellitus) . Mol Nutr Food Res . 2005;49:274–284
View In Article
MEDLINE
CrossRef
Cavin C , Holzhaeuser D , Scharf G , et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity . Food Chem Toxicol . 2002;40:1155–1163
View In Article
MEDLINE
CrossRef
Cardenas C , Quesada AR , Medina MA , et al. Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene . PLoS One . 2011;6:e23407
View In Article
CrossRef
Bravi F , Bosetti C , Tavani V , et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis . Hepatology . 2007;46:430–435
View In Article
CrossRef
Panchal SK , Poudyal H , Waanders J , et al. Coffee extract attenuates changes in cardiovascular function and hepatic structure and function without decreasing obesity in high-carbohydrate, high-fat diet-fed male rats . J Nutrition . 2012;142:690–697
View In Article
Birerdinc A , Stepanova M , Pawloski L , et al. Caffeine is protective in patients with non-alcoholic fatty liver disease . Aliment Pharmacol Ther . 2012;35:76–82
View In Article
CrossRef
Shi X , Dalal NS , Jain AC . Antioxidant behavior of caffeine: efficient scavenging of hydroxyl radicals . Food Chem Toxicol . 1991;29:1–6
View In Article
MEDLINE
CrossRef
Anty R , Marjoux S , Iannelli A , et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery . J Hepatol . 2012;57:1090–1096
View In Article
Abstract
Full Text
Full-Text PDF (587 KB)
CrossRef
Klatsky AL , Armstrong MA . Alcohol, smoking, coffee, and cirrhosis . Am J Epidemiol . 1992;136:1248–1257
View In Article
MEDLINE
Ruhl CE , Everhart JE . Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States . Gastroenterology . 2005;128:24–32
View In Article
Abstract
Full Text
Full-Text PDF (127 KB)
CrossRef
Ruhl CE , Everhart JE . Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States . Gastroenterology . 2005;129:1928–1936
View In Article
Abstract
Full Text
Full-Text PDF (155 KB)
CrossRef
Larsson SC , Wolk A . Coffee consumption and risk of liver cancer: a meta-analysis . Gastroenterology . 2007;132:1740–1745
View In Article
Abstract
Full Text
Full-Text PDF (244 KB)
CrossRef
Freedman ND , Everhart JE , Lindsay KL , et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C . Hepatology . 2009;50:1360–1369
View In Article
CrossRef
Leung WW , Ho SC , Chan HL , et al. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study . J Epidemiol Community Health . 2011;65:556–558
View In Article
Johnson S , Koh WP , Wang R , et al. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study . Cancer Causes Control . 2011;22:503–510
View In Article
CrossRef
Costentin CE , Roudot-Thoraval F , Zafrani E , et al. Association of caffeine intake and histological features of chronic hepatitis C . J Hepatol . 2011;54:1123–1129
View In Article
Abstract
Full Text
Full-Text PDF (685 KB)
CrossRef
Matsuura H , Mure K , Nishio N , et al. Relationship between coffee consumption and prevalence of metabolic syndrome among Japanese civil servants . J Epidemiol . 2012;22:160–166
View In Article
CrossRef
Gutierrez-Grobe Y , Chavez-Tapia N , Sanchez-Valle V , et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity . Ann Hepatol . 2012;11:350–355

EASL- Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C


Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C at EASL 2013 

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

“TG4040 has recently completed successful phase 2 trial in patients with CHC”

Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products – TG1050 and TG4040 to treat chronic hepatitis B (CHB) and chronic hepatitis C (CHC), respectively – will be presented in oral presentations at this year’s European Association for the Study of the Liver (EASL) Conference (Amsterdam, Netherlands, April 24-28, 2013). The full abstracts are available at http://www.easl.eu.

“We are delighted to have the opportunity to present data at EASL, Europe’s largest liver conference. TG1050 is a novel immunotherapeutic to treat CHB that has shown very promising preclinical results and will soon be moving to early clinical development” stated Philippe Archinard, Chairman and CEO of Transgene. He added: “In addition to the preclinical proof-of-concept data published in September 20121, we have today released supplementary information, obtained in pre-clinical naïve and HBV murine models, on the immunogenicity of TG1050 and its capacity to induce long-term T cell response. This evidence further underlines our belief in the product’s potential to become an important new first in class immunotherapeutic to treat CHB, an area of unmet medical need.”

“TG4040 has recently completed successful phase 2 trial in patients with CHC” stated Nathalie Adda, Chief Medical Officer of Transgene. She added: “Following interim data published in April last year for TG4040 in combination with PegIFNα2a and ribavirin, we report the final results of the phase 2 HCVac trial with sustained viral response at 24 weeks (SVR24) and additional immunogenicity, specific T-cell and humoral responses. The study has demonstrated that pre-treatment with TG4040 has a positive impact on viral response as shown by cEVR and SVR improvement compared to PegIFN alpha 2a and Ribavirin alone. HCV Immunotherapy now could be explored in combination with an IFN-free DAA regimen.”

1 Poster Presentation of TG1050 at the International HBV Meeting in Oxford, England

The oral presentations will take place on Friday, April 26 and Saturday, April 27, 2013.

Friday, April 26, Session entitled: HCV Direct Acting Antivirals (abstract No 62)

Phase 2 HCVac Study of TG4040 immunotherapeutic in combination with PegIFNα2a and ribavirin in genotype 1 CHC treatment naïve patients: SVR24 Final Results

Oral presentation by Pr. Heiner Wedemeyer, Principal Investigator of the HCVac study, University of Hanover, Germany

Session Time: 16:00-18:00

Saturday, April 27, Session entitled: Hepatitis B and D Experimental (abstract No 130)

A Multivalent Adenovirus-Based Immunotherapeutic for Treatment of Chronic Hepatitis B Induces Broad, Robust and Polyfunctional T Cells in Naïve and HBV Tolerant Mice

Oral presentation by Dr. Perrine Martin, Scientific Coordinator of the Hepatitis B Program, Department of Infectious Diseases, Transgene SA.

Session Time: 15:30-17:30

About TG1050

The novel immunotherapeutic product TG1050 developed by Transgene to treat chronic infection by hepatitis B is based on a recombinant non-replicative human adenovirus serotype 5, expressing multiple specific HBV antigens (Core, Polymerase and Envelope) from genotype D. The product has been designed to prime de novo and/or stimulate functional T cells expected to control the HBV replication and to elicit viral clearance.

According to the World Health Organization’s (WHO) estimates, 350 million people are chronic carriers (WHO, 2009) of HBV. Hepatitis B is more common in some parts of the world than others. In China and other parts of Asia, up to 10% of the population is believed to be chronically infected. In addition to the significant burden of disease, CHB is responsible for 1 million deaths each year due to related complications such as liver failure, cirrhosis or hepatocellular carcinoma (liver cancer).

About TG4040

Transgene’s TG4040 vaccine candidate is a recombinant vector based on the MVA virus carrying and expressing three of the major non-structural proteins (NS3, NS4 and NS5B) of the hepatitis C virus (HCV). The MVA vector is a highly attenuated strain of vaccinia virus, which has been tested extensively in humans as a vaccine against smallpox and is known to strongly stimulate innate and adaptive immune responses to antigens.

About TG4040 Clinical Development Program

153 patients in the phase 2 HCVac study were recruited in five countries in Europe, in the United States and in Israel, and were randomized in one control arm (Arm A; 48 weeks of Peg-IFN/RBV) or one of the two experimental arms (Arms B and C). In the Arm B, the TG4040 dosage (subcutaneous injections at the dose of 107 pfu) was administered 6 times and Peg-IFN/RBV was given 4 weeks prior to the initiation of TG4040. In the Arm C, the TG4040 dosage was administered 13 times and Peg-IFN/RBV was introduced 12 weeks after the initiation TG4040. The HCVac trial investigated the efficacy and safety of these two different schedules of TG4040 administration in combination with Peg-IFN and RBV.

About Transgene:

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for the treatment of cancers and infectious diseases. Transgene’s products are major technological breakthroughs. They use well tolerated viruses to indirectly or directly kill infected or cancerous cells. Its four most advanced products have generated proof of concept data in randomized clinical studies: in lung cancer (TG4010), liver cancer (Pexa-Vec), hepatitis C (TG4040) and HPV-related cervical lesions (TG4001). Transgene has concluded strategic agreements for the development of three of these products: an option agreement with Novartis for the development of TG4010, an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec and a strategic collaboration with EORTC to develop TG4001 in cancer of the oropharynx. Transgene also has a non exclusive agreement with Sanofi/Genzyme for its future commercial production. With 280 employees, it is based in Strasbourg, France, and has operations in Lyon, China and the USA. Additional information about Transgene is available at www.transgene.fr.

Transgene Forward Looking Statements

This press release contains forward-looking statements notably referring to an anticipated future BLA filing date by Transgene. Such anticipated future BLA filing date is based on the current plan of product development and testing. This plan may change in the future and, as such, Transgene could be in a position not to meet the currently anticipated development milestones, including such BLA filing. For further information on the risks and uncertainties involved in the testing and development of Transgene’s product candidates, see Trangene’s Document de Référence on file with the French Autorité des marchés financiers on its website at http://www.amffrance.org and on Transgene’s website at www.transgene.fr .

Société anonyme au capital de 72.886.317 € – R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation - CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 (0)3 88 27 91 00 

Contacts

Transgene
Philippe Archinard, +33 (0)3 88 27 91 22
Chairman & CEO
or
Stéphane Boissel, +33 (0)3 88 27 91 02
Executive Vice President & CFO
or
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director IR
or
MC Services
Raimund Gabriel, +49 89 210 228 30
or
Shaun Brown, +44 207 148 5998

EASL-Bristol-Myers Squibb to Present New Data on Hepatitis C and Hepatitis B Compounds

Bristol-Myers Squibb to Present New Data on Hepatitis C and Hepatitis B Compounds at The International Liver CongressTM (ILC) 2013

   
  • New data on an investigational, all-oral, triple DAA regimen of daclatasvir, asunaprevir and BMS-791325 to be included in official ILC Press Conference on April 24
  • New ALT flare data further characterize profile of peginterferon lambda-1a (Lambda) as investigational treatment for Chronic Hepatitis B (CHB)
  • Breadth of data underscores Company’s commitment to advancing the treatment of liver disease


PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that 14 abstracts on the Company’s research in liver disease have been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the Study of the Liver (EASL), in Amsterdam, April 24 – 28.
   
“The data we are presenting at the International Liver Congress demonstrate our continued advancement of research to address unmet medical needs, through the development of regimens for personalized hepatitis C treatment and increasing options to treat hepatitis B.”

Key presentations include:
  • New Phase 2 data on an investigational triple direct-acting antiviral (DAA) regimen of daclatasvir (NS5A replication complex inhibitor), asunaprevir (NS3 protease inhibitor) and BMS-791325 (NS5B non-nucleotide polymerase inhibitor) in patients with hepatitis C (HCV) genotypes 1a and 1b. The regimen is being studied as a potential interferon alfa-, ribavirin- and ritonavir-free treatment option to avoid the tolerability and drug-drug interaction profiles of these medicines. These triple DAA data will be highlighted in the official ILC Press Conference on April 24.
  • An analysis of all available safety data on 1,100 patients who received daclatasvir plus interferon alfa and ribavirin in Phase 2 studies. These data support the ongoing Phase 3 development program for daclatasvir and further studies of daclatasvir as a component of DAA-based HCV treatment regimens.
  • A characterization of ALT flares observed in hepatitis B (HBV) treatment with the investigational interferon Lambda vs. alfa interferon, reflecting differing profiles for the two compounds. Lambda is being developed as a potential alternative for alfa wherever interferon is used in the treatment of either HCV or HBV.
  • An analysis of sustained virologic response with daclatasvir plus sofosbuvir, with or without ribavirin, in patients with HCV genotype 1 who previously failed telaprevir or boceprevir.
“Bristol-Myers Squibb has a longstanding commitment to viral hepatitis and has been at the forefront of the evolving science in both hepatitis B and C,” said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb. “The data we are presenting at the International Liver Congress demonstrate our continued advancement of research to address unmet medical needs, through the development of regimens for personalized hepatitis C treatment and increasing options to treat hepatitis B.”

Bristol-Myers Squibb is studying a portfolio of compounds that has the potential to address unmet medical needs for patients with liver disease, including the investigational compounds daclatasvir, asunaprevir and BMS-791325 for HCV, and Lambda for HCV and HBV. In addition to these compounds, the Company’s medicine BARACLUDE® (entecavir) is approved for the treatment of chronic hepatitis B (CHB) in adults with evidence of active viral replication and either evidence of persistent elevations in aminotransferases (ALT or AST), or histologically active disease.
The complete list of Bristol-Myers Squibb data presentations is below. Abstracts can be accessed on the ILC/EASL website at http://www.easl.eu/_the-international-liver-congress/general-information.
   
Title   Date/Time
Hepatitis C: Direct-Acting Antiviral Data
     
Synergistic Interactions of HCV NS5A replication Complex Inhibitors Sensitize Resistant Variants and Enhance the Efficacy of Daclatasvir (DCV, BMS-790052) In Vitro and In Vivo
         
  April 25
12:15 – 1:30 pm
Asunaprevir with Peginterferon and Ribavirin in Treatment-Naïve Patients with Genotype –1 or -4 Chronic Hepatitis C: SVR24 Results From a Randomized Phase 2b Study (AI447016)
       
  April 25
12:15 – 1:30 pm
Evaluation of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, an NS5B Non-Nucleotide Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in HCV Genotype 1-Infected Patients   April 25
12:15 – 1:30 pm
The Effect of Coadministration of the Proton-Pump Inhibitor Omeprazole on the Pharmacokinetics of Daclatasvir in Healthy Subjects   April 26
12:30 – 2:00 pm
Exposure-Response Analyses of Asunaprevir in Combination with Daclatasvir ± Peginterferon / Ribavirin Among Patients with Genotype 1 Chronic HCV Infection: Dose Selection for Phase 3 Clinical Trials
-Response Analyses of Asunaprevir in Patients with Genotype 1, Chronic HCV Infection: Dose Selection for Phase 3 Clinical Trials
  April 26
12:30 – 2:00 pm
Daclatasvir Combined With Peginterferon Alfa and Ribavirin for 12 or 16 Weeks in Patients With HCV Genotype 2 or 3 Infection: COMMAND GT2/3 Study
  April 27
3:30 – 5:30 pm
Oral presentation
Sustained Virologic Response with Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) In Chronic HCV Genotype (GT) 1-Infected Patients who Previously Failed Telaprevir (TVR) or Boceprevir (BOC)   April 27
3:30 – 5:30 pm
Oral presentation
Safety Profile of Daclatasvir in Combination with Peginterferon Alfa and Ribavirin in 1100 Patients with Chronic HCV Infection Treated in Phase 2 Studies   April 27
12:30 – 1:30 pm
Pre-Existence, Emergence and Persistence of HCV Genotype 4 NS5A Resistance Variants from the Phase 2b COMMAND-1 Study: Daclatasvir Plus Peginterferon-Alfa/Ribavirin in Treatment-Naïve Patients
         
  April 27
12:30 – 1:30 pm
Hepatitis C: Outcomes Research Data
Host Genetic Variants Around IL28A/IL28B Associated with HCV-Related Outcomes Based on R.E.V.E.A.L.-HCV Cohort
  April 25
12:15 – 1:30 pm
Genome-Wide Association Study to Identify Potential Single Nucleotide Polymorphisms Associated with Spontaneous Hepatitis C Virus Clearance Among Chronic Hepatitis C Patients
         
  April 25
12:15 – 1:30 pm
Hepatitis B: Peginterferon Lambda-1a Data
ALT Flares During Treatment With Peginterferon Lambda or Peginterferon Alfa in Patients with HBeAg-Positive Chronic Hepatitis B Infection (CHB)   April 26
12:30 – 2:00 pm
Hepatitis B: BARACLUDE® (entecavir) Data
Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients   April 26
12:30 – 2:00 pm
 
INDICATION and IMPORTANT SAFETY INFORMATION about BARACLUDE® (entecavir) Tablets:
   
INDICATION
BARACLUDE is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
The following points should be considered when initiating BARACLUDE:
  • This indication is based on histologic, virologic, biochemical, and serologic responses in nucleoside-treatment-naïve and lamivudine-resistant adult subjects with HBeAg-positive or HBeAg-negative chronic HBV infection and compensated liver disease.
  • Virologic, biochemical, serologic, and safety data are available from a controlled study in adult subjects with chronic HBV infection and decompensated liver disease.
  • Virologic, biochemical, serologic, and safety data are available for a limited number of adult subjects with HIV/HBV co-infection who have received prior lamivudine therapy.
IMPORTANT SAFETY INFORMATION
WARNINGS: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY
  • Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
  • Limited clinical experience suggests there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if BARACLUDE (entecavir) is used to treat chronic HBV infection in patients with HIV infection that is not being treated. Therapy with BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART).
  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, alone or in combination with antiretrovirals.
Warnings and Precautions
  • Before initiating BARACLUDE® (entecavir) therapy, HIV antibody testing should be offered to all patients. BARACLUDE has not been studied as a treatment for HIV infection and is not recommended for this use.
  • Lactic acidosis with BARACLUDE use has been reported, often in association with hepatic decompensation, other serious medical conditions, or drug exposures. Patients with decompensated liver disease may be at higher risk for lactic acidosis. BARACLUDE should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity.
Adverse Reactions
  • In clinical trials in patients with compensated liver disease, the most common (≥3%) adverse reactions of any severity with at least a possible relation to study drug for BARACLUDE-treated subjects were headache, fatigue, dizziness, and nausea. In these trials, the most common adverse reactions of moderate to severe intensity (grades 2-4) were diarrhea, dyspepsia, nausea, vomiting, fatigue, headache, dizziness, somnolence, and insomnia.
  • In the decompensated liver disease trial, the most common adverse reactions of any severity among patients treated with BARACLUDE, regardless of causality, included: peripheral edema (16%), ascites (15%), pyrexia (14%), hepatic encephalopathy (10%), and upper respiratory infection (10%). In this trial, 18% (18/102) of BARACLUDE (entecavir) patients and 20% (18/89) of adefovir patients died during the first 48 weeks of therapy. The majority of those deaths were due to liver related causes.
Drug Interactions
BARACLUDE is primarily eliminated by the kidneys, therefore coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug. Patients should be monitored closely when receiving BARACLUDE® (entecavir) with other renally-eliminated drugs.
   
Pregnancy and Nursing Mothers
  • There are no adequate and well-controlled studies of BARACLUDE in pregnant women. BARACLUDE should be used during pregnancy only if clearly needed and after careful consideration of the risks and benefits.
  • There are no studies on the effect of BARACLUDE on transmission of HBV from mother to infant. Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV.
  • It is not known whether BARACLUDE is excreted into human milk; however, many drugs are excreted into breast milk. Due to the potential for serious adverse reactions in nursing infants from BARACLUDE, risks and benefits should be considered when deciding whether to discontinue breast-feeding or discontinue BARACLUDE in nursing women.
Pediatric Use
  • Safety and effectiveness of BARACLUDE in pediatric patients below the age of 16 years have not been established.
Renal Impairment
  • Dosage adjustment of BARACLUDE is recommended for patients with a creatinine clearance <50 mL/min, including those on hemodialysis or continuous ambulatory peritoneal dialysis.
Liver Transplant Recipients
  • Renal function must be carefully monitored both before and during treatment with BARACLUDE in a liver transplant recipient who has received or is receiving an immunosuppressant that may affect renal function, such as cyclosporine or tacrolimus.
Dosage and Administration
BARACLUDE® (entecavir) should be administered on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal).
The recommended dose of BARACLUDE:
  • in nucleoside-naïve adults and adolescents (16+ yrs) with compensated liver disease is 0.5 mg once daily
  • in adults and adolescents (16+ yrs) with compensated liver disease, and refractory to lamivudine or with known lamivudine or telbivudine resistance mutations (rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L) is 1 mg once daily
  • in adults with decompensated liver disease is 1 mg once daily
The optimal duration of treatment with BARACLUDE for patients with chronic HBV infection and the relationship between treatment and long-term outcomes such as cirrhosis and hepatocellular carcinoma are unknown.
   
Additional Information
BARACLUDE is not a cure for HBV. Patients should be advised that treatment with BARACLUDE has not been shown to reduce the risk of transmission of HBV to others through sexual contact or blood contamination.
Please see accompanying Full Prescribing Information, including Boxed WARNINGS, or click here.
    
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
    
Bristol-Myers Squibb Forward Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the clinical trials of these compounds will support regulatory filings, or that the compounds will receive regulatory approvals or, if approved, that they will become commercially successful products. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
BARACLUDE® (entecavir) is a registered trademark of Bristol-Myers Squibb.

Contacts
 
Media:
Sonia Choi, 609-252-5132
sonia.choi@bms.com
or
Carrie Fernandez, 609-252-4831
carrie.fernandez@bms.com
or
Investors:
John Elicker, 609-252-4611
john.elicker@bms.com
or
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Ryan Asay, 609-252-5020
ryan.asay@bms.com

EASL-Merck to Present New Data on VICTRELIS® (boceprevir) and MK-5172/Vaniprevir

Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck’s investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. The meeting will take place in Amsterdam from April 24-28, 2013. 
    
Key Presentations About VICTRELIS 200 mg Capsules

  • Safety And Efficacy Of Boceprevir/Peginterferon/Ribavirin (Boc/P/R) Combination Therapy For Chronic HCV G1 Patients With Compensated Cirrhosis: A Meta-Analysis Of Five Phase III Clinical Trials, J.M. Vierling et al. Late Breaker. Thursday, April 25, 9:00- 18:00. RAI Convention Centre.
  • Virologic Response Rates Are Similar In Previously Untreated And Previously Treated And Relapsed Patients Receiving Boceprevir Triple Therapy: A Retrospective Analysis. Bacon, B. et al. Poster 791. Friday, April 26, 12:30-14:00. RAI Convention Centre.

Key Investigational Compound Presentations
  • High Sustained Viral Response at 12- and 24-week follow-up of MK-5172 with Pegylated Interferon alfa-2b and Ribavirin (PR) in HCV Genotype 1 Treatment-naïve Non-cirrhotic Patients. Manns, M. et al. Oral Presentation: Friday, April 26, 16:00-18:00, RAI Convention Centre.
  • MK-5172 In Combination With Peg-Interferon And Ribavirin Elicits Limited Resistance While Demonstrating Robust Efficacy In Treatment Naïve Genotype 1 Chronic HCV-Infected Patients. Howe, A. et al. Poster 1197. Saturday, April 27, 12:30-13:30. RAI Convention Centre.
  • Sustained Viral Response And Safety Of MK-7009 In Cirrhotic Treatment-Experienced Patients With Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon And Ribavirin Treatment. Rodriguez-Torres, M. et al. Oral Presentation. Saturday, April 27, 8:30-10:30. RAI Convention Centre.

"We are pleased to present new data on VICTRELIS that will help inform health care professionals as they consider the use of VICTRELIS in appropriate patients," said Eliav Barr, M.D., vice president, Infectious Diseases, Project Leadership and Management, Merck Research Laboratories. "Merck is committed to helping reduce the burden of this serious disease worldwide. We look forward to sharing our new data about VICTRELIS and Merck's investigational medicines for chronic hepatitis C with the global scientific community."

MK-5172 is an investigational, once-daily, oral HCV NS3/4A protease inhibitor currently in Phase II development. Vaniprevir is an oral, twice-daily HCV NS3/4A protease inhibitor in Phase III development in Japan for the treatment of genotype 1 patients.
The abstracts were published today and can be accessed on the EASL website. For program information, please visit http://www2.kenes.com/liver-congress/pages/home.aspx.

Indications and usage for VICTRELIS
VICTRELIS® (boceprevir) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 (G1) infection, in combination with peginterferon alfa and ribavirin (PR), in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy, including prior null responders, partial responders, and relapsers.

The following points should be considered when initiating VICTRELIS for treatment of chronic HCV infection:


  • VICTRELIS must not be used as monotherapy and should only be used in combination with PR.
  • The efficacy of VICTRELIS has not been studied in patients who have previously failed therapy with a treatment regimen that includes VICTRELIS or other HCV NS3/4A protease inhibitors.
  • Poorly interferon responsive patients who were treated with VICTRELIS in combination with PR have a lower likelihood of achieving a sustained virologic response (SVR), and a higher rate of detection of resistance-associated substitutions upon treatment failure, compared to patients with a greater response to PR.

All contraindications to PR also apply since VICTRELIS must be administered with PR. Because ribavirin may cause birth defects and fetal death, VICTRELIS in combination with PR is contraindicated in pregnant women and in men whose female partners are pregnant. Avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to therapy; have monthly pregnancy tests; and use 2 or more forms of effective contraception during treatment and for at least 6 months after treatment has concluded. One of these forms of contraception can be a combined oral contraceptive product containing at least 1 mg of norethindrone. Oral contraceptives containing lower doses of norethindrone and other forms of hormonal contraception have not been studied or are contraindicated.    

VICTRELIS is contraindicated in patients with a history of a hyperse
nsitivity reaction to VICTRELIS. VICTRELIS is contraindicated in coadministration with drugs that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. VICTRELIS is also contraindicated in coadministration with potent CYP3A4/5 inducers, where significantly reduced VICTRELIS plasma concentrations may be associated with reduced efficacy. Drugs that are contraindicated with VICTRELIS include: alfuzosin, carbamazepine, phenobarbital, phenytoin, rifampin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, St. John’s Wort (hypericum perforatum), lovastatin, simvastatin, drospirenone, Revatio® (sildenafil) or Adcirca® (tadalafil) (when used for the treatment of pulmonary arterial hypertension), pimozide, triazolam, and orally administered midazolam.

Anemia and/or Neutropenia – The addition of VICTRELIS to PR is associated with an additional decrease in hemoglobin concentrations compared with PR alone and/or may result in worsening of neutropenia associated with PR therapy alone. Dose reduction or discontinuation of peginterferon alfa and/or ribavirin may be required. If peginterferon alfa or ribavirin is permanently discontinued, VICTRELIS must also be discontinued. Dose reduction of VICTRELIS is not recommended. VICTRELIS must not be administered in the absence of PR.

Complete blood count (with white blood cell differential counts) must be conducted in all patients prior to initiating combination therapy with VICTRELIS. Complete blood counts should be obtained at Treatment Weeks 2, 4, 8, and 12, and should be monitored closely at other time points, as clinically appropriate. Serious acute hypersensitivity reactions (eg, urticaria, angioedema) have been observed during combination therapy with VICTRELIS and PR. If such an acute reaction occurs, combination therapy should be discontinued and appropriate medical therapy immediately instituted.

The most commonly reported adverse reactions (>35%) in clinical trials in adult patients receiving the combination of VICTRELIS with PR were: fatigue, anemia, nausea, headache, and dysgeusia. Of these commonly reported adverse reactions, fatigue, anemia, nausea, and dysgeusia occurred at rates ≥5% above the rates for PR alone in either clinical study. The incidence of these adverse reactions in previously untreated subjects that were treated with combination therapy with VICTRELIS compared with PR alone were: fatigue (58% vs 59%), anemia (50% vs 30%), nausea (46% vs 42%), and dysgeusia (35% vs 16%), respectively. The incidence of these adverse reactions in previous treatment failure patients that were treated with combination therapy with VICTRELIS compared with PR alone were: fatigue (55% vs 50%), anemia (45% vs 20%), nausea (43% vs 38%), and dysgeusia (44% vs 11%), respectively.

VICTRELIS is a strong inhibitor of CYP3A4/5 and is partly metabolized by CYP3A4/5. The potential for drug-drug interactions must be considered prior to and during therapy.
Please see U.S. prescribing information at: http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf

Merck's Global Commitment to Advancing Hepatitis Therapy
Merck is committed to building on its strong legacy in the field of viral hepatitis by continuing to discover, develop and deliver vaccines and medicines to help prevent and treat viral hepatitis. In hepatitis C, company researchers developed the first approved therapy for chronic HCV in 1991 and the first combination therapy in 1998. In addition to ongoing studies for our marketed and investigational medicines for the treatment of chronic HCV, extensive research efforts are underway to develop additional innovative oral therapies for viral hepatitis treatment.

About Merck
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
 
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.


Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
    
Please see Prescribing Information for VICTRELIS at http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf and Medication Guide for VICTRELIS at http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_mg.pdf.

EASL-Boehringer Ingelheim will announce pivotal Phase III hepatitis C data

Boehringer Ingelheim will announce pivotal Phase III hepatitis C data at the International Liver Congress (ILC / EASL)

April 8, 2013 at 12:37 pm · Filed under Business


INGELHEIM, Germany – Monday, April 8th 2013 [ME NewsWire]

(BUSINESS WIRE)– For media outside of the U.S.A., UK and Canada only

Results from Boehringer Ingelheim’s pivotal STARTVerso™1 Phase III hepatitis C clinical trial have been accepted for oral presentation at the International Liver Congress™ (ILC*) 2013, 24-28 April, Amsterdam. The data have also been selected for inclusion in the official ILC Press Conference on 24 April at 11:00 CEST. The abstract will be published online on 23 April at 12:00 CEST when the embargo is lifted.

The STARTVerso™1 trial assessed faldaprevir+ (BI 201335), an investigational NS3/4A protease inhibitor that is taken orally once-daily in combination with pegylated interferon and ribavirin (PegIFN/RBV) versus placebo with PegIFN/RBV. The study was conducted in treatment-naïve genotype-1 patients, the most common and one of the most challenging HCV patient populations to cure.1 Faldaprevir was tested at two doses, 120mg and 240mg once daily, the primary endpoint was sustained virological response 12 weeks after planned end of treatment (SVR 12).

This faldaprevir based treatment regimen has the potential to improve viral cure rates and tolerability for the patient. Boehringer Ingelheim is developing faldaprevir, an optimised second generation protease inhibitor, as the core component for both interferon-based and interferon-free hepatitis C treatment regimens.

Three additional sub-analyses from the Phase IIb SOUND-C2 study will also be presented at the congress. The SOUND-C2 trial investigated the interferon-free combination of faldaprevir and BI 207127+, a potent investigational non-nucleoside NS5B polymerase inhibitor, with ribavirin. These data result from Boehringer Ingelheim’s comprehensive clinical trial program which includes a diverse population of hepatitis C patients. The company is dedicated to develop effective and well tolerated treatments recognising the high unmet need for more patient centric approaches in HCV.

Boehringer Ingelheim’s data due to be presented in poster form can be accessed through the congress website today: http://www.sessionplan.com/EASL2013/

Oral Presentations

Title

Lead Author

Presentation details

First data from the Phase III STARTVersoTM1 clinical trial; investigating faldaprevir (BI 201335) in combination with pegylated interferon and ribavirin, in TN, GT-1 HCV patients

P. Ferenci

24 April @ 11 CET (as part of the official ILC™ Press Conference)

27 April @ 15:30 CET (as part of the ILC™ scientific programme)

Poster Presentations

Title

Lead Author

Presentation details

An analysis of response rates by fibrosis stage in patients treated with faldaprevir, BI 207127 and ribavirin in the SOUND-C2 study2

S. Zeuzem

Abstract number 1227

27 April 09:00-18:00

Poster Session, P03-08d, Category 08d: Viral Hepatitis C: Clinical (new compounds, resistance)

ITPA gene variants predict haemolytic ribavirin induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in SOUND-C23

T. Asselah

Abstract number 1186

27 April 09:00-18:00

Poster Session, P03-08d, Category 08d: Viral Hepatitis C: Clinical (new compounds, resistance)

The relationship between sustained virological response and plasma concentrations of faldaprevir or BI 207127 in HCV GT1-infected patients in SOUND-C24

S. Olson

Abstract number 1212

27 April 09:00-18:00

Poster Session, P03-08d, Category 08d: Viral Hepatitis C: Clinical (new compounds, resistance)

*International Liver Congress™ 2013: 48th Annual Meeting of the European Association for the Study of the Liver

+faldaprevir and BI 207127 are investigational compounds and not yet approved. Their safety and efficacy have not yet been fully established

# # #

NOTES TO EDITORS

The Boehringer Ingelheim NewsHome: An innovative resource for journalists

The Boehringer Ingelheim hepatitis C http://www.NewsHome.com is now available and is the one-stop-shop for clear, concise and easy to understand information about hepatitis C.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsibly. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales. Updated 2012 data will be provided at Boehringer Ingelheim’s Annual Press Conference on 24 April 2013. If you are interested in attending please email: press@boehringer-ingelheim.com

For more information please visit http://www.boehringer-ingelheim.com

References:

1. Ferenci P. et al. STARTVersoTM1 data. To be presented at EASL 2013

2. Zeuzem S. et al. An analysis of response rates by fibrosis stage in patients treated with faldaprevir, BI 207127 and ribavirin in the SOUND-C2 study. To be presented at EASL 2013

3. Asselah T. et al. ITPA gene variants predict haemolytic ribavirin induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in SOUND-C2. To be presented at EASL 2013

4. Olsen. S. et al. Pharmacokinetic modelling of the relationship between sustained virological response and plasma concentrations of faldaprevir or BI 207127 in HCV GT1-infected patients in SOUND-C2. To be presented at EASL 2013

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Reinhard Malin

Tel: +49 (6132) 77-90815

Email: press@boehringer-ingelheim.com

More information

http://www.boehringer-ingelheim.com

EASL-Medivir: Data from Simeprevir in Hepatitis C Patients Will Be Presented

Medivir: Data from Simeprevir in Hepatitis C Patients Will Be Presented at EASL During 24-28 April in Amsterdam

STOCKHOLM — Medivir AB (OMX: MVIR) (STO:MVIR-B) today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands. These data presentations will include primary efficacy and safety results from the phase III QUEST-1 study of simeprevir administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients

Simeprevir is an investigational NS3/4A protease inhibitor, administered as a 150 mg capsule once daily in combination with pegylated interferon and ribavirin jointly developed by Medivir and Janssen Pharmaceuticals, Inc. (Janssen).

Janssen recently submitted new drug applications in Japan and the United States for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients. We anticipate a submission of simeprevir for regulatory authorization in the EU in the first half of 2013.

Simeprevir is also being studied in combination with pegylated interferon and ribavirin for the treatment of genotype 4 HCV infection and in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

Additional simeprevir data from the QUEST-2 study have been accepted by The International Liver Congress, but are subject to EASL’s embargo policy until April 23. The data to be presented at The International Liver Congress 2013 include:

Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial
Available Thursday, April 25 – Saturday, April 27    

Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment
Available Friday, April 26

Improved SVR with simeprevir (TMC435) associated with reduced time with patient-reported fatigue in treatment-naïve, HCV-infected patients in the PILLAR phase IIb trial
Available Friday, April 26

Adding simeprevir (TMC435) to pegylated interferon/ribavirin does not increase patient reported fatigue in treatment-experienced patients with chronic HCV infection: results from the ASPIRE trial
Available Friday, April 26

Combination therapy of TMC647055 with simeprevir (TMC435) in genotype 1 HCV patients

Full session details and data presentation listings for The International Liver Congress 2013 can be found at http://www.easl.eu.

About Simeprevir

Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease. Janssen recently announced the submission of new drug applications for simeprevir in Japan and the United States for the treatment of genotype 1 hepatitis C.

Global phase III studies of simeprevir include QUEST-1 and QUEST-2 in treatment-naïve patients, PROMISE in patients who have relapsed after prior interferon-based treatment and ATTAIN in null-responder patients. In parallel to these trials, phase III studies for simeprevir are ongoing in treatment-naïve and treatment-experienced HIV-HCV co-infected patients and HCV genotype 4 patients.

Simeprevir is also being studied in phase II interferon-free trials with and without ribavirin in combination with:
Janssen’s non-nucleoside inhibitor TMC647055 and ritonavir in treatment-naïve genotype 1a and 1b HCV patients; · Gilead Sciences, Inc.’s nucleotide inhibitor sofosbuvir (GS-7977) in treatment-naïve and previous null-responder genotype 1 HCV patients; and · Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir (BMS-790052) in treatment-naive and previous null-responder genotype 1 HCV patients.

In addition, Janssen has entered into a non-exclusive collaboration with Vertex Pharmaceuticals to evaluate in a phase II study the safety and efficacy of an all-oral regimen of simeprevir and Vertex’s investigational nucleotide analogue polymerase inhibitor VX-135 for the treatment of HCV. As a first step, Janssen Pharmaceutical Inc. will conduct a drug-drug interaction (DDI) study with simeprevir and VX-135.

Janssen also has plans to initiate a phase II trial of an investigational interferon-free regimen with simeprevir, TMC647055 and Idenix’s IDX719, a once-daily, pan-genotypic NS5A inhibitor, with and without ribavirin.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Hepatitis C

Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease and liver transplants, is a rapidly evolving treatment area with a clear need for innovative treatments. Approximately 150 million people are infected with hepatitis C worldwide, and 350,000 people per year die from the disease.

About Medivir AB

Medivir is an emerging research-based pharmaceutical company focused on infectious diseases.

Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor in late phase III clinical development for hepatitis C that is being developed in collaboration with Janssen R&D Ireland. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website: www.medivir.com

This information was brought to you by Cision http://news.cision.com



Sunday, April 7, 2013

Sofosbuvir/ Ledipasvir -An ‘apocalypse moment’ for HCV?

GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.

View Current Issue 

(VOL. 7 NO. 5 APRIL 2013):
PDF | Interactive Version

Issue Highlights

Interferon-free HCV regimen cured all genotype 1 patients
Included: sofosbuvir, ledipasvir, ribavirin..

BY PATRICE WENDLING IMNG
Medical News ATLANTA –

Adding ledipasvir to sofosbuvir and ribavirin produced sustained virological responses 12 weeks after therapy in 100% of treatment-naive and prior nonresponder patients with chronic hepatitis C genotype 1 in the ELECTRON trial. “Certainly adding a second direct-acting antiviral agent, ledipasvir, increases the efficacy of sofosbuvir plus ribavirin,” Dr. Edward Gane said at the Conference on Retroviruses and Opportunistic Infections. Three-quarters of the roughly 170 million people infected with hepatitis C virus (HCV) worldwide have genotype 1, the most difficult strain to treat. Current treatment includes triple therapy with a protease inhibitor plus peginterferon and ribavirin for 24-48 weeks, but PIbased therapy is limited by complex dosing regimens, the potential for resistance, and lower responses in prior nonresponders, explained Dr. Gane of Auckland Clinical Studies in New Zealand. The investigators hypothesized that combining two direct-acting antivirals with a different mechanism would enhance response.......

Ledipasvir and sofosbuvir have been combined into a single fixeddose tablet and it is being evaluated in phase III studies in patients with cirrhosis and to determine whether there is a need for ribavirin, he said. Additional studies are also underway to explore shorter durations of therapy. The ELECTRON trial was sponsored by Gilead Sciences. Dr. Gane reported ties with Gilead, Janssen- Cilag, Novartis, Pharmasset, Roche and Vertex...............


P E R S P E C T I V E
An ‘apocalypse moment’ for HCV?

Current therapeutic approaches to treatment of chronic HCV genotype 1 are limited by troublesome side effects, long courses of therapy, drug-drug interactions, and regimens that include pegylated interferon (administered by injection) and a protease inhibitor (administered thrice daily with food). Many patients are ineligible for therapy because of contraindications to the medications.
Furthermore, the current regimens do not have high efficacy in null responders. This has provided the impetus to develop all-oral regimens with better efficacy, improved side-effect profiles, and shorter courses of therapy.
These results of the phase II ELECTRON trial arm testing the all-oral regimen of sofosbuvir (NS5b polymerase inhibitor), ledipasvir (NS5a inhibitor), and weight based ribavirin in patients with chronic HCV genotype 1 (without cirrhosis) add to the recent number of stunning reports describing all oral treatment regimens for chronic HCV.
Such therapeutic approaches offer the promise of tolerable regimens that have outstanding efficacy and may have few or no contraindications to therapy.
It is unclear if patients with cirrhosis will respond as well as noncirrhotic patients did in ELECTRON and whether or not ribavirin is needed; phase III trials are currently underway to address these issues. If the phase II results are replicated in these phase III trials and if the medications are available to all patients who have chronic HCV genotype 1, this type of a regimen could represent the “apocalypse moment” for HCV, when the most common type of HCV worldwide (genotype 1) is largely eliminated.

Steven L. Flamm, M.D., is chief of transplant hepatology and is professor of medicine in the division of gastroenterology and hepatology at Northwestern University Feinberg School of Medicine, Chicago. He disclosed receiving research support from Gilead and serving as an advisor to the company......

Everolimus approved for liver transplant indication

Food and Drug Administration approval of the immunosuppressant drug everolimus has been expanded to include prophylaxis of organ rejection in adults undergoing a liver transplant....

Alpha-fetoprotein useful marker in HCC

Changes in serum alpha-fetoprotein levels over time correlated with the development of hepatocellular carcinoma in hepatitis C patients, wrote Dr. Elliot Lee and his colleagues in the April issue of Clinical Gastroenterology and Hepatology.......

Continue to website.......

Download
PDF | Interactive Version